This Plain Language Summary of Publication from Future Oncology describes the results from a study called CheckMate 649, the study looked into whether combining Nivolumab , an immunotherapy, with chemotherapy would help people with advanced stomach or oesophageal cancer live longer without their cancer getting worse.
Read the full article here.
The original article on which this plain language summary is based is titled ‘First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial’ and was published in the Lancet. Read the original article here.